olaparib + abiraterone

This combination consists of **olaparib**, a PARP inhibitor (poly [ADP-ribose] polymerase inhibitor), and **abiraterone**, an androgen biosynthesis inhibitor. Together, they are approved for the treatment of **metastatic castration-resistant prostate cancer (mCRPC)**, particularly for patients with deleterious or suspected deleterious BRCA-mutated tumors, as determined by an FDA-approved companion diagnostic test. Olaparib impairs DNA repair in tumor cells, particularly those with homologous recombination repair deficiencies (like BRCA mutations), leading to apoptosis. Abiraterone inhibits CYP17 and thus androgen (testosterone) production, which prostate cancer depends on for growth. The combination extends radiographic progression-free survival versus abiraterone alone and is associated with more frequent high-grade anemia and other toxicities. Approval is based on improved outcomes predominantly in BRCA-mutant mCRPC populations[1][3][4][5].

Brand names

Lynparza (for olaparib)Zytiga (for abiraterone)

Other names

olaparib plus abirateroneolaparib and abirateroneolaparib combined with abiraterone